CHP
CLSD

Cable Hill Partners’s Clearside Biomedical CLSD Stock Holding History

Cable Hill Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-67
Closed -$7K – 896
2017
Q4 		$7K Buy
+67
New +$7.19K ﹤0.01% 647

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Cable Hill Partners's CLSD Position: Q1 2018 in Review

Cable Hill Partners sold out of Clearside Biomedical (CLSD) in Q1 2018, closing a stake of 67 shares — an estimated $7K sold.

Cable Hill Partners first reported a position in CLSD in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 79 funds tracked by Wall St. Rank hold CLSD as of Q1 2018.

  • Cable Hill Partners reported no remaining Clearside Biomedical position as of Q1 2018 after selling out during the quarter.
  • Cable Hill Partners sold 67 Clearside Biomedical shares in Q1 2018, an estimated $7K.
  • Cable Hill Partners first reported a position in Clearside Biomedical in Q4 2017 and held it in 1 quarter.
  • Cable Hill Partners's Clearside Biomedical position peaked at $7K in Q4 2017.
  • 79 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2018.

Based on Cable Hill Partners's 13F filing for Q1 2018, filed 20 Apr 2018.